Anthony A. Gostanian

Public Company Transactions & Representation

Mr. Gostanian regularly represents public biotech and life sciences companies in corporate governance and securities law compliance matters, as well as strategic transactions, including:

• Ligand Pharmaceuticals in its:
  • Acquisition of Pfenex, Inc.
  • Acquisition of Open Monoclonal Technologies
  • Offering of US$750 million convertible notes
• Zogenix, Inc., a global biopharmaceutical company that develops and commercializes therapies for rare diseases, in its:
  • Acquisition of Modis Pharmaceuticals
  • Initial public offering and follow-on offerings
• Phathom Pharmaceuticals in its initial public offering and follow-on offerings
• Oncternal Therapeutics, an oncology company, in reverse merger transaction with GTx
• Evoke Pharma, Inc., a pharmaceutical company focused on the treatment of gastrointestinal diseases, in its initial public offering and follow-on offerings
• Extra Space Storage LP, a provider of self-storage units, in equity offerings and its acquisition of SmartStop Self Storage

Underwriters

Mr. Gostanian routinely advises leading investment banks, such as JPMorgan, Jeffries, and SVB Leerink, as underwriters in public equity offerings, including for:

• Arrowhead Pharmaceuticals, Inc.
• Castle Biosciences, Inc.
• Equillium
• Genmark Diagnostics, Inc.
• Heron Therapeutics, Inc.
• Immunogen, Inc.
• Iovance Biotherapeutics, Inc.
• Mirati Therapeutics, Inc.
• Poseida Therapeutics
• Regulus Therapeutics Inc.
• Retrophin, Inc.
• Rigel Pharmaceuticals, Inc.
• Synthorx, Inc.
• Veracyte, Inc.

Thought Leadership

Author, “How the FDA Can Overturn Wyeth v. Levine,” 36 American Journal of Law & Medicine 248, 2010